Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Posts Quarterly Earnings Results, Meets Expectations

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) released its quarterly earnings data on Tuesday. The company reported $0.30 EPS for the quarter, hitting analysts’ consensus estimates of $0.30, FiscalAI reports. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The firm had revenue of $243.60 million for the quarter, compared to the consensus estimate of $226.49 million.

Kiniksa Pharmaceuticals International Trading Up 1.1%

KNSA opened at $63.53 on Tuesday. Kiniksa Pharmaceuticals International has a twelve month low of $26.51 and a twelve month high of $67.53. The firm has a market cap of $4.89 billion, a price-to-earnings ratio of 70.59 and a beta of 0.07. The company has a fifty day simple moving average of $57.07 and a 200 day simple moving average of $50.18.

Wall Street Analyst Weigh In

Several research firms recently weighed in on KNSA. Citigroup raised their price objective on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Wells Fargo & Company boosted their price target on Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. Finally, The Goldman Sachs Group lifted their price objective on Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the company a “buy” rating in a research report on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International has a consensus rating of “Buy” and a consensus target price of $68.00.

Insider Activity at Kiniksa Pharmaceuticals International

In other news, insider John F. Paolini sold 58,424 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $53.71, for a total value of $3,137,953.04. Following the completion of the sale, the insider directly owned 65,623 shares in the company, valued at approximately $3,524,611.33. The trade was a 47.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the completion of the transaction, the chief executive officer directly owned 48,565 shares of the company’s stock, valued at $2,623,481.30. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 131,674 shares of company stock worth $7,094,671 over the last 90 days. 51.98% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. EverSource Wealth Advisors LLC raised its stake in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares in the last quarter. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth $31,000. Smartleaf Asset Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth $36,000. CIBC Private Wealth Group LLC purchased a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth approximately $41,000. Finally, Quantbot Technologies LP acquired a new position in Kiniksa Pharmaceuticals International in the 2nd quarter worth approximately $43,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.